LIVE WEBINAR: Tuesday, November 1, 2022, 5:00 PM – 6:00 PM Eastern Time

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer

A CME/MOC-Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Tuesday, November 1st for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Stephen V Liu, MD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Tuesday, November 1, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • MODULE 1: Current Utility of Immunotherapy-Based Strategies for Advanced NSCLC
  • MODULE 2: Future Directions and Postimmunotherapy Management of Advanced NSCLC

Target Audience
This activity is intended for medical and radiation oncologists, nurses and other allied healthcare professionals involved in the treatment of non-small cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy, chemobiologic therapy or other immunotherapy for metastatic non-small cell lung cancer (NSCLC), and consider the clinical and biologic factors affecting the recommendation of one approach versus the others.
  • Review available Phase III research data documenting the efficacy and safety of durvalumab in combination with tremelimumab and chemotherapy as first-line treatment for NSCLC, in preparation for the potential availability of this novel regimen.
  • Evaluate the current scientific understanding of mechanisms of primary and acquired resistance to immune checkpoint inhibition in patients with NSCLC, and consider the implications for biomarker assessment and disease management.
  • Recall ongoing clinical trials and emerging data with promising novel agents and strategies in clinical development for patients with primary or acquired resistance to immune checkpoint inhibition.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr HeymachAdvisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Janssen Biotech Inc, Kairos Venture Investments LLC, Leads Biolabs, Lilly, Mirati Therapeutics Inc, Nexus Health Systems, Novartis, Pneuma Respiratory, RefleXion, Roche Laboratories Inc, Sanofi Genzyme, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Spectrum Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: BrightPath Biotherapeutics Co Ltd; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc; Speaker's Bureau: IDEOlogy Health. Dr LiuAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, Eisai Inc, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Novartis, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Catalyst Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck Sharp & Dohme LLC, Novartis, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Contracted Research: Alkermes, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Merus BV, Nuvalent, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: Candel.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.